2021
Hypomethylating Agents and FLT3 Inhibitors As Maintenance Treatment for Acute Myeloid Leukemia and Myelodysplastic Syndrome After Allogeneic Hematopoietic Stem Cell Transplantation–A Systematic Review and Meta-Analysis
Bewersdorf JP, Allen C, Mirza AS, Grimshaw AA, Giri S, Podoltsev NA, Gowda L, Cho C, Tallman MS, Zeidan AM, Stahl M. Hypomethylating Agents and FLT3 Inhibitors As Maintenance Treatment for Acute Myeloid Leukemia and Myelodysplastic Syndrome After Allogeneic Hematopoietic Stem Cell Transplantation–A Systematic Review and Meta-Analysis. Transplantation And Cellular Therapy 2021, 27: 997.e1-997.e11. PMID: 34551341, PMCID: PMC9533376, DOI: 10.1016/j.jtct.2021.09.005.Peer-Reviewed Original ResearchConceptsAcute myeloid leukemiaRelapse-free survivalMaintenance therapyMyelodysplastic syndromeFLT3 inhibitorsAllo-HCTHazard ratioMaintenance treatmentClinical trialsMyeloid leukemiaAllogeneic hematopoietic stem cell transplantationControl groupSystematic reviewAllogeneic hematopoietic cell transplantMeasurable residual disease statusHematopoietic stem cell transplantationMeasurable residual disease testingNon-relapse mortalityHematopoietic cell transplantPre-emptive treatmentResidual disease statusStem cell transplantationFavorable safety profileSame patient cohortRandom-effects modelOutcomes of Allogeneic Hematopoietic Cell Transplantation in Patients With Myelofibrosis—A Systematic Review and Meta-Analysis
Bewersdorf JP, Sheth AH, Vetsa S, Grimshaw A, Giri S, Podoltsev NA, Gowda L, Tamari R, Tallman MS, Rampal RK, Zeidan AM, Stahl M. Outcomes of Allogeneic Hematopoietic Cell Transplantation in Patients With Myelofibrosis—A Systematic Review and Meta-Analysis. Transplantation And Cellular Therapy 2021, 27: 873.e1-873.e13. PMID: 34052505, PMCID: PMC8478722, DOI: 10.1016/j.jtct.2021.05.016.Peer-Reviewed Original ResearchConceptsConditioning regimen intensityAllo-HCTRegimen intensityChronic graftTransplant characteristicsGraft failureOverall survivalPatient ageSubgroup analysisDynamic International Prognostic Scoring System scoresSystematic reviewAllogeneic hematopoietic cell transplantationInternational Prognostic Scoring System scoreCurative therapeutic modalityNon-relapse mortalityTransplant-related mortalityMedian patient ageOutcomes of patientsSecondary graft failureCo-primary outcomesHematopoietic cell transplantHematopoietic cell transplantationRandomized clinical trialsHeterogeneity of patientsRandom-effects model
2019
Evaluation of Efficacy and Safety of Front-Line Regimens for the Treatment of Transplant Ineligible Patients with Multiple Myeloma: A Network Meta-Analysis of Phase 2/3 Randomized Controlled Trials
Giri S, Aryal M, Yu H, Grimshaw A, Pathak R, Huntington S, Dhakal B. Evaluation of Efficacy and Safety of Front-Line Regimens for the Treatment of Transplant Ineligible Patients with Multiple Myeloma: A Network Meta-Analysis of Phase 2/3 Randomized Controlled Trials. Blood 2019, 134: 2188. DOI: 10.1182/blood-2019-130389.Peer-Reviewed Original ResearchProgression-free survivalOverall response rateHematopoietic cell transplantFront-line treatmentAdverse eventsOverall survivalMM patientsMultiple myelomaFrontline regimensClinical trialsAdvisory CommitteeCommon grade 3Cumulative ranking (SUCRA) probabilitiesFront-line regimensHigher adverse eventsPrimary efficacy outcomeTransplant-ineligible patientsPhase III RCTsNetwork Meta-AnalysisBias assessment toolRisk of biasEvaluation of efficacyIndividual patient needsEfficacious regimenEfficacious regimens